Gina Mauro

The findings came from a post-hoc analysis of the phase 3 ARCHES trial.

Long-term data from the phase 3 JAVELIN Bladder 100 trial continued to show an overall survival (OS) boost with frontline avelumab maintenance in patients with metastatic urothelial cancer.

The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to abiraterone acetate in the frontline setting significantly improved radiographic progression-free survival versus placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer.

“Although numbers of participants with certain disease risk features were small, the DFS benefit was consistent across subgroups,” said lead study author Toni K. Choueiri, MD.

Men whose tumors are microsatellite instability–high or mismatch repair–deficient may have a greater response to immune checkpoint blockade compared with patients with high tumor mutational burden.

“The combination of Vicineum and durvalumab in BCG-unresponsive NMIBC is tolerated well and no new safety signals were identified; the doublet has a similar safety profile to [what is seen with] both agents used individually,” says Sandeep Gurram, MD.

Avelumab is approved by the FDA for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.

Findings from the phase 3 KEYNOTE-564 trial showed that adjuvant pembrolizumab significantly improved disease-free survival versus placebo in patients with clear cell renal cell carcinoma.

The subgroup analysis assessed data from the pivotal phase 3 JAVELIN Bladder 100 trial showed.

The multikinase inhibitor showed significant intracranial and extracranial responses in patients with metastatic renal cell carcinoma and brain metastases.

An analysis from the pivotal phase 3 JAVELIN Bladder 100 trial showed that the survival benefit observed with frontline maintenance avelumab in the overall population was sustained across several prespecified patients subgroups.

The combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

The addition of the AKT inhibitor ipatasertib to abiraterone acetate and prednisone improved radiographic progression-free survival, with overall survival data still eagerly anticipated.